PL432011A1 - Biomarkery miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca - Google Patents

Biomarkery miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca

Info

Publication number
PL432011A1
PL432011A1 PL432011A PL43201119A PL432011A1 PL 432011 A1 PL432011 A1 PL 432011A1 PL 432011 A PL432011 A PL 432011A PL 43201119 A PL43201119 A PL 43201119A PL 432011 A1 PL432011 A1 PL 432011A1
Authority
PL
Poland
Prior art keywords
mirna
panel
mirna biomarkers
biomarkers
differential
Prior art date
Application number
PL432011A
Other languages
English (en)
Other versions
PL241607B1 (pl
Inventor
Radosław CHARKIEWICZ
Attila GYENESEI
Bence GÁLIK
Jacek NIKLIŃSKI
Joanna RESZEĆ
Mirosław KOZŁOWSKI
Anetta SULEWSKA
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL432011A priority Critical patent/PL241607B1/pl
Priority to PCT/PL2019/000113 priority patent/WO2021107791A1/en
Publication of PL432011A1 publication Critical patent/PL432011A1/pl
Publication of PL241607B1 publication Critical patent/PL241607B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem niniejszego wynalazku jest sposób różnicowego diagnozowania in vitro raka gruczołowego płuca (AC) względem raka płaskonabłonkowego płuca (SCC) u osobnika, w którym to sposobie oznacza się ilościowo poziom ekspresji dla panelu wyselekcjonowanych biomarkerów miRNA i identyfikuje się sygnaturę miRNA. Przedmiotem niniejszego wynalazku jest ponadto sposób różnicowego diagnozowania in vitro raka płaskonabłonkowego płuca (SCC) względem raka gruczołowego płuca (AC) u osobnika, w którym to sposobie oznacza się ilościowo poziom ekspresji dla panelu wyselekcjonowanych biomarkerów miRNA i identyfikuje się sygnaturę miRNA. Przedmiotem wynalazku jest również panel wyselekcjonowanych biomarkerów miRNA oraz zastosowania takiego panelu biomarkerów miRNA w diagnostyce. Przedmiotem wynalazku jest ponadto zestaw do różnicowego diagnozowania in vitro raka gruczołowego płuca względem raka płaskonabłonkowego płuca zawierający środki do ilościowego oznaczania poziomu ekspresji panelu biomarkerów miRNA oraz zestaw do różnicowego diagnozowania in vitro raka płaskonabłonkowego płuca względem raka gruczołowego płuca zawierający środki do ilościowego oznaczania poziomu ekspresji panelu biomarkerów miRNA.
PL432011A 2019-11-29 2019-11-29 Panel biomarkerów miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca PL241607B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL432011A PL241607B1 (pl) 2019-11-29 2019-11-29 Panel biomarkerów miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca
PCT/PL2019/000113 WO2021107791A1 (en) 2019-11-29 2019-11-30 Mirna biomarkers for differential diagnosis of histopathological subtypes of non-small cell lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432011A PL241607B1 (pl) 2019-11-29 2019-11-29 Panel biomarkerów miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca

Publications (2)

Publication Number Publication Date
PL432011A1 true PL432011A1 (pl) 2021-05-31
PL241607B1 PL241607B1 (pl) 2022-11-07

Family

ID=69374347

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432011A PL241607B1 (pl) 2019-11-29 2019-11-29 Panel biomarkerów miRNA do diagnozowania różnicowego podtypów histopatologicznych niedrobnokomórkowego raka płuca

Country Status (2)

Country Link
PL (1) PL241607B1 (pl)
WO (1) WO2021107791A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116334230B (zh) * 2023-05-08 2026-06-02 天津市肿瘤医院（天津医科大学肿瘤医院） 一种肺腺癌标志物及其在制备肺腺癌筛查试剂盒或治疗监测试剂盒中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076145A1 (en) * 2009-12-24 2011-06-30 Fudan University Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer
US9914972B2 (en) * 2011-03-28 2018-03-13 Rosetta Genomics Ltd. Methods for lung cancer classification

Also Published As

Publication number Publication date
PL241607B1 (pl) 2022-11-07
WO2021107791A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
Shinozaki‐Ushiku et al. Diagnostic utility of BAP 1 and EZH 2 expression in malignant mesothelioma
AU2020336115A8 (en) Characterizing methylated DNA, RNA, and proteins in subjects suspected of having lung neoplasia
Litvak et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging
Brunner et al. Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV
Kutlu et al. Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients
EP4464797A3 (en) Kit, device, and method for detecting lung cancer
NZ597363A (en) Prognosis prediction for colorectal cancer
WO2020041243A8 (en) Methods related to bronchial premalignant lesion severity and progression
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
NZ624816A (en) Ratio based biomarkers and methods of use thereof
WO2022174234A3 (en) Biomarkers for cancer treatment
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
BR112017016808A2 (pt) biomarcadores para câncer pancreático
Ferro et al. High-grade T1 on re-transurethral resection after initial high-grade T1 confers worse oncological outcomes: results of a multi-institutional study
MX2020014091A (es) Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
Zhang et al. Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer
MY193895A (en) Combination test for colorectal cancer
GB201222576D0 (en) Method for diagnosing lung cancer
CL2020003204A1 (es) Tratamiento de nsclc en etapa iii y mitigación de condiciones patológicas asociadas al tratamiento
WO2016005905A3 (en) Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages
MX2021010449A (es) Metodos y composiciones para tratar cancer.
WO2020264379A8 (en) Markers for the diagnosis of prostate cancer
ES2672989T3 (es) FALZ para su uso como diana para terapias para tratar el cáncer
EP3557259A3 (en) Methods and arrays for use in the same